Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, November 26, 2025

Evaluating the Safety and Effectiveness of Perispinal Etanercept for Post-Stroke Recovery: A Systematic Review

 

Finally proof on this. Here's all the previous unproven writeups on this and the stuff from Dr. Tobinick's unproven uses.

You'll want to read all of the previous posts on Etanercept for other uses and risks and the previous unproven uses. Unless you really think your doctor has a good handle on this.

  • etanercept (43 posts to February 2011)
  • dr. Tobinick (33 posts to November 2012)

    • Evaluating the Safety and Effectiveness of Perispinal Etanercept for Post-Stroke Recovery: A Systematic Review

    Meha Sanghi • Nawat Khanijoun • Nahla Hamza

    Published: November 12, 2025

    DOI: 10.7759/cureus.96707 

    Open Access
    Peer-Reviewed
    Cite this article as: Sanghi M, Khanijoun N, Hamza N (November 12, 2025) Evaluating the Safety and Effectiveness of Perispinal Etanercept for Post-Stroke Recovery: A Systematic Review . Cureus 17(11): e96707. doi:10.7759/cureus.96707

    Abstract

    Stroke remains a leading cause of long-term disability in adults, with many survivors experiencing persistent neurological and functional deficits. Conventional rehabilitation offers limited benefit once recovery plateaus. Biological therapies targeting chronic mechanisms of neural dysfunction, such as perispinal etanercept (PSE), a tumor necrosis factor-alpha (TNF-α) inhibitor, have been proposed as potential alternatives. This systematic review evaluates the safety and effectiveness of PSE for neurological recovery in adults with chronic post-stroke deficits. A comprehensive search of PubMed, Embase, MEDLINE, Cochrane Library, Scopus, and Web of Science identified human studies assessing PSE in stroke ≥six months post-event. Two reviewers independently screened, extracted data, and assessed bias using the risk of bias 2 (RoB 2), Newcastle-Ottawa Scale, and Joanna Briggs Institute (JBI) tools. Eligible studies included randomised trials, non-randomised trials, and case-based reports describing neurological, functional, cognitive, or safety outcomes. Five studies met the inclusion criteria: two randomised controlled trials, one large observational cohort, one case series, and one case report. The available evidence showed variable outcomes. Some studies reported short-term improvements in pain and motor function, whereas others found no significant overall functional or quality-of-life gains. Reported benefits, when observed, were typically domain-specific and not consistently sustained. Treatment was well tolerated, with no major safety concerns reported. Robust, large-scale trials are still needed to establish consistent functional benefits and long-term efficacy. Future research should focus on optimising treatment protocols and identifying responsive patient phenotypes through neuroimaging and inflammatory biomarkers. Well-designed multicenter trials with standardised stroke-specific endpoints and extended follow-up are essential to determine the true therapeutic value of PSE before routine clinical adoption.












     
    Posted by at
    Labels: ,

    No comments:

    Post a Comment

    Subscribe to: Post Comments (Atom)